REXAHN PHARMACEUTICALS, INC. Contracts & Agreements
194 Contracts & Agreements
- Business Finance (82 contracts)
- Business Operations (13)
- Human Resources (49)
- Intellectual Property (5)
- Mergers & Acquisitions (3)
- Real Estate (13)
- Uncategorized (29)
- Consulting Agreement between Ocuphire Pharma, Inc. and Jay Pepose, M.D., dated April 11, 2024 (Filed With SEC on April 17, 2024)
- Fifth Lease Amendment, dated as of November 29, 2023, by and between the Company and Duke & Duke (Filed With SEC on March 8, 2024)
- Employment Agreement, dated February 13, 2024, by and between the Company and Nirav Jhaveri (Filed With SEC on February 16, 2024)
- First Amendment to Employment Agreement, entered into on February 16, 2024, by and between the Company and Nirav Jhaveri (Filed With SEC on February 16, 2024)
- Amended and Restated Employment Agreement, dated as of April 24, 2023, by and between Ocuphire Pharma, Inc. and Ronil Patel (Filed With SEC on December 6, 2023)
- First Amendment to Amended and Restated Employment Agreement, dated as of December 1, 2023, by and between Ocuphire Pharma, Inc. and Ronil Patel (Filed With SEC on December 6, 2023)
- Offer Letter entered into on November 20, 2023 by and between Ocuphire Pharma, Inc. and Joseph Schachle (Filed With SEC on November 27, 2023)
- Employment Agreement entered into on October 31, 2023 by and between Ocuphire Pharma, Inc. and George Magrath (Filed With SEC on November 1, 2023)
- Form of Restricted Stock Unit Award and Form of Award Agreement (Filed With SEC on November 1, 2023)
- First Amendment to 2021 Inducement Plan (Filed With SEC on November 1, 2023)
- Separation and Release Agreement by and between Ocuphire Pharma, Inc. and Mina Sooch, dated June 8, 2023 (Filed With SEC on August 11, 2023)
- Purchase Agreement, dated as of August 10, 2023, by and between Ocuphire Pharma, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 11, 2023)
- Registration Rights Agreement, dated as of August 10, 2023, by and between Ocuphire Pharma, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 11, 2023)
- Interim President and CEO Consulting Letter Agreement by and between Ocuphire Pharma, Inc. and Richard Rodgers, dated April 20, 2023 (Filed With SEC on May 15, 2023)
- Non-Employee Director Compensation Policy (Filed With SEC on May 15, 2023)
- First Amendment to the Amended and Restated Employment Agreement by and among the Company and Mina Sooch, effective as of March 26, 2023 (Filed With SEC on March 30, 2023)
- First Amendment to the Amended and Restated Employment Agreement by and among the Company and Bernhard Hoffmann, effective as of March 26, 2023 (Filed With SEC on March 30, 2023)
- Form of Restricted Stock Unit Grant Notice issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 30, 2023)
- Form of Stock Option Grant Notice issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 30, 2023)
- Form of Stock Option Grant Notice issued under the Ocuphire Pharma, Inc. 2021 Inducement Plan (Filed With SEC on March 30, 2023)
- First Amendment to the Employment Agreement by and among the Company and Amy Rabourn, effective as of March 26, 2023 (Filed With SEC on March 30, 2023)
- First Amendment to the Consulting Agreement dated September 19, 2022, by and between the Company and Jay Pepose (Filed With SEC on March 30, 2023)
- Second Amendment to the Consulting Agreement dated December 1, 2022, by and between the Company and Jay Pepose (Filed With SEC on March 30, 2023)
- License and Collaboration Agreement dated as of November 6, 2022 by and between Ocuphire Pharma, Inc. and Famy (Filed With SEC on November 7, 2022)
- Fourth Lease Amendment, dated as of October 17, 2022 (Filed With SEC on November 4, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on August 12, 2022)
- Consulting Agreement between the Registrant and Jay Pepose dated April 8, 2022 (Filed With SEC on May 13, 2022)
- Third Lease Amendment, dated as of September 9, 2021, by and between the Company and Duke & Duke (Filed With SEC on November 12, 2021)
- License Agreement dated June 16, 2021 (Filed With SEC on June 23, 2021)
- Placement Agency Agreement, dated as of June 4, 2021, by and between Ocuphire Pharma, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on June 7, 2021)
- Form of Warrant to purchase shares of common stock (Filed With SEC on June 7, 2021)
- Form of Securities Purchase Agreement, dated as of June 4, 2021, by and among Ocuphire Pharma, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on June 7, 2021)
- Placement Agency Agreement, dated as of June 4, 2021, by and between Ocuphire Pharma, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on June 4, 2021)
- Form of Warrant to purchase shares of common stock (Filed With SEC on June 4, 2021)
- Form of Securities Purchase Agreement, dated as of June 4, 2021, by and among Ocuphire Pharma, Inc. and the purchasers identified on the signature pages thereto (Filed With SEC on June 4, 2021)
- Description of Securities (Filed With SEC on March 11, 2021)
- Form of Lock-Up Agreement, by and between the Company, OcuSub, Inc. and certain stockholders (Filed With SEC on March 11, 2021)
- Ocuphire Pharma, Inc. 2020 Inducement Plan (Filed With SEC on March 11, 2021)
- Employment Agreement dated November 11, 2020, by and between the Company and Amy Rabourn (Filed With SEC on March 11, 2021)
- Second Lease Amendment, dated as of November 17, 2020, by and between the Company and Duke & Duke (Filed With SEC on March 11, 2021)
- Capital on Demand Sales Agreement, dated March 11, 2021 between Ocuphire Pharma, Inc. and JonesTrading Institutional Services LLC (Filed With SEC on March 11, 2021)
- Form of Waiver Agreement, dated as of February 3, 2021, by and between Ocuphire Pharma, Inc. and the Holder(s) (Filed With SEC on February 4, 2021)
- Contingent Value Rights Agreement, dated as of November 5, 2020, by and among the Company, Shareholder Representative Services LLC and the Olde Monmouth Stock Transfer Co., Inc (Filed With SEC on November 6, 2020)
- Form of Indemnity Agreement between the Company and each of its directors and executive officers (Filed With SEC on November 6, 2020)
- Non-Employee Director Compensation Policy of the Company (Filed With SEC on November 6, 2020)
- Warrant Exchange Agreement, dated September 10, 2020, by and between Rexahn Pharmaceuticals, Inc. and Empery Asset Master, Ltd (Filed With SEC on September 11, 2020)
- Warrant Exchange Agreement, dated September 10, 2020, by and between Rexahn Pharmaceuticals, Inc. and Empery Tax Efficient, LP (Filed With SEC on September 11, 2020)
- Warrant Exchange Agreement, dated September 10, 2020, by and between Rexahn Pharmaceuticals, Inc. and Empery Tax Efficient II, LP (Filed With SEC on September 11, 2020)
- Warrant Exchange Agreement, dated September 1, 2020, by and between Rexahn Pharmaceuticals, Inc. and Anson Investments Master Fund LP (Filed With SEC on September 2, 2020)
- Agreement and Plan of Merger, dated as of June 17, 2020, by and among the Company, Merger Sub and Ocuphire (Filed With SEC on August 14, 2020)
- Warrant Exchange Agreement, dated July 31, 2020, by and between Rexahn Pharmaceuticals, Inc. and Armistice Capital Master Fund Ltd (Filed With SEC on August 3, 2020)
- Stockholders Agreement, dated as of April 10, 2018, among Ocuphire Pharma, Inc. and Stockholders as defined therein (Filed With SEC on July 6, 2020)
- Employment Agreement, dated as of October 1, 2018, between Ocuphire Pharma, Inc. and Mina Sooch (Filed With SEC on July 6, 2020)
- Amended and Restated Employment Agreement by and among Ocuphire Pharma, Inc. and Mina Sooch, to be effective as of the Closing (Filed With SEC on July 6, 2020)
- Employment Agreement, dated as of October 1, 2018, between Ocuphire Pharma, Inc. and Bernhard Hoffmann (Filed With SEC on July 6, 2020)
- Amended and Restated Employment Agreement by and among Ocuphire Pharma, Inc. and Bernhard Hoffmann, to be effective as of the Closing (Filed With SEC on July 6, 2020)
- Form of Indemnification Agreement (Filed With SEC on July 6, 2020)
- Sublicense Agreement, dated as of January 21, 2020, by and between Ocuphire Pharma, Inc. and Apexian Pharmaceuticals, Inc (Filed With SEC on July 6, 2020)
- First Amendment to Sublicense Agreement, dated as of June 4, 2020, by and between Apexian Pharmaceuticals, Inc. and Ocuphire Pharma, Inc (Filed With SEC on July 6, 2020)
- Lease Agreement, dated as of May 19, 2019, by and between Ocuphire Pharma, Inc. and Duke & Duke, LP (Filed With SEC on July 6, 2020)
- First Amendment to Lease Agreement, dated as of October 29, 2019, by and between Ocuphire Pharma, Inc. and Duke & Duke, LP (Filed With SEC on July 6, 2020)
- Ocuphire Pharma, Inc. 2018 Equity Incentive Plan, dated as of April 9, 2019 (Filed With SEC on July 6, 2020)
- First Amendment to 2018 Equity Incentive Plan, dated as of December 23, 2019 (Filed With SEC on July 6, 2020)
- Form of Option Agreement issuable under the Ocuphire Pharma, Inc. 2018 Equity Incentive Plan (Filed With SEC on July 6, 2020)
- Amended and Restated Mezz Note Purchase Agreement, dated as of January 22, 2019, by and among Ocuphire Pharma, Inc. and each of the purchasers set forth therein (Filed With SEC on July 6, 2020)
- First Amendment to Amended and Restated Mezz Note Purchase Agreement, dated as of November 20, 2019, by and among Ocuphire Pharma, Inc. and each of the purchasers party to the... (Filed With SEC on July 6, 2020)
- Note Conversion Agreement, dated as of June 8, 2020, by and among Ocuphire Pharma, Inc. and each of the purchasers party to the Amended and Restated Mezz Note Purchase Agreement (Filed With SEC on July 6, 2020)
- First Amendment to Agreement and Plan of Merger and Reorganization, dated as of June 29, 2020, by and among Rexahn, Merger Sub and Ocuphire (Filed With SEC on July 1, 2020)
- Form of Series A/B Warrants (Filed With SEC on July 1, 2020)
- Amended and Restated Securities Purchase Agreement, dated as of June 29, 2020, by and among Rexahn, Ocuphire and the investors party thereto (Filed With SEC on July 1, 2020)
- Form of Financing Lock-Up Agreement, by and among Rexahn, Ocuphire, and the investors party thereto (Filed With SEC on July 1, 2020)
- Form of Leak-Out Agreement, by and between Rexahn and the investors party thereto (Filed With SEC on July 1, 2020)
- Agreement and Plan of Merger, dated as of June 17, 2020, by and among Rexahn, Merger Sub and Ocuphire (Filed With SEC on June 19, 2020)
- Form of Series A/B Warrants (Filed With SEC on June 19, 2020)
- Registration Rights Agreement, dated June 17, 2020, by and among Rexahn and certain investors named therein (Filed With SEC on June 19, 2020)
- Form of CVR Agreement, by and among Rexahn, the CVR Representative, and the Rights Agent (Filed With SEC on June 19, 2020)
- Form of Ocuphire Voting Agreement, by and among Ocuphire, Rexahn and certain stockholders of Ocuphire (Filed With SEC on June 19, 2020)
- Form of Lock-Up Agreement, by and among Rexahn, Ocuphire and certain stockholders of Rexahn and Ocuphire (Filed With SEC on June 19, 2020)
- Securities Purchase Agreement, dated as of June 17, 2020, by and among Rexahn, Ocuphire and the investors party thereto (Filed With SEC on June 19, 2020)
- Form of Financing Lock-Up Agreement, by and among Rexahn, Ocuphire, and the investors party thereto (Filed With SEC on June 19, 2020)
- Form of Leak-Out Agreement, by and between Rexahn and the investors party thereto (Filed With SEC on June 19, 2020)
- Amendment No. 2 to Collaboration and License Agreement, dated as of March 10, 2020 between BioSense Global LLC and Rexahn Pharmaceuticals, Inc (Filed With SEC on May 7, 2020)
- Description of Common Stock (Filed With SEC on February 21, 2020)
- Amendment No. 1 to Collaboration and License Agreement (Filed With SEC on August 29, 2019)
- Collaboration and License Agreement, dated as of February 25, 2019, between BioSense Global LLC and Rexahn Pharmaceuticals, Inc (Filed With SEC on August 7, 2019)
- Sixth Amendment to Lease Agreement, dated as of March 18, 2019, by and between the registrant and SG Plaza Holdings, LLC (Filed With SEC on May 10, 2019)
- Form of Restricted Stock Unit Agreement under the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (Filed With SEC on March 7, 2019)
- Underwriting Agreement, dated January 23, 2019, by and between Rexahn Pharmaceuticals, Inc. and Oppenheimer & Co. Inc (Filed With SEC on January 25, 2019)
- Form of Warrant (Filed With SEC on January 25, 2019)
- Amendment to Employment Agreement dated November 14, 2018 (Filed With SEC on November 16, 2018)
- Separation, Transition and General Release Agreement dated November 14, 2018 (Filed With SEC on November 16, 2018)
- Clinical Trial Collaboration and Supply Agreement, dated August 13, 2018, by and between Merck Sharp & Dohme B.V., and Rexahn Pharmaceuticals, Inc (Filed With SEC on November 2, 2018)
- Engagement Letter, dated as of October 16, 2018, by and between Rexahn Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 19, 2018)
- Form of Warrant (Filed With SEC on October 19, 2018)
- Form of Securities Purchase Agreement, dated as of October 17, 2018, by and between Rexahn Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on October 19, 2018)
- Separation, Transition and General Release Agreement, dated as of December 11, 2017, by and between Rexahn Pharmaceuticals, Inc. and Tae Heum (Ted) Jeong (Filed With SEC on March 9, 2018)
- Employment Agreement by and between Rexahn Pharmaceuticals, Inc. and Douglas Swirsky effective January 2, 2018 (Filed With SEC on January 4, 2018)
- Engagement Letter, dated as of October 12, 2017, by and between Rexahn Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 13, 2017)
- Form of Warrant (Filed With SEC on October 13, 2017)
- Form of Securities Purchase Agreement, dated as of October 13, 2017, by and between Rexahn Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on October 13, 2017)
- Fifth Amendment to Lease Agreement, dated April 13, 2017, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza Holdings, LLC (Filed With SEC on August 4, 2017)
- Engagement Letter, dated as of June 5, 2017 by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on June 7, 2017)
- Form of Warrant (Filed With SEC on June 7, 2017)
- Form of Securities Purchase Agreement, dated as of June 6, 2017, by and between Rexahn Pharmaceuticals, Inc. and the investors in the offering (Filed With SEC on June 7, 2017)
- First Amendment to the Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as Amended and Restated as of June 9, 2016 (Filed With SEC on April 13, 2017)
- Employment Agreement dated July 6, 2016 by and between Rexahn Pharmaceuticals, Inc. and Lisa Nolan, Ph.D (Filed With SEC on November 4, 2016)
- Engagement Letter, dated as of September 13, 2016 by and between Rexahn Pharmaceuticals, Inc and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on September 14, 2016)
- Form of Warrant (Filed With SEC on September 14, 2016)
- Form of Securities Purchase Agreement, dated as of September 14, 2016, by and between Rexahn Pharmaceuticals, Inc. and the investors in the offering (Filed With SEC on September 14, 2016)
- Fourth Amendment to Lease Agreement, dated April 4, 2016, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza Holdings, LLC (Filed With SEC on August 5, 2016)
- Bonus Letter Agreement, dated August 2, 2016, by and between Rexahn Pharmaceuticals, Inc. and Ely Benaim, M.D (Filed With SEC on August 5, 2016)
- Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan, as Amended and Restated (Filed With SEC on June 10, 2016)
- Form of Stock Option Grant Agreement under Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (Filed With SEC on March 14, 2016)
- Engagement Letter, dated as of February 26, 2016 by and between Rexahn Pharmaceuticals, Inc and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on February 26, 2016)
- Form of Warrant (Filed With SEC on February 26, 2016)
- Form of Securities Purchase Agreement, dated as of February 26, 2016, by and between Rexahn Pharmaceuticals, Inc. and the investor in the offering (Filed With SEC on February 26, 2016)
- Engagement Letter, dated as of November 5, 2015, by and between Rexahn Pharmaceuticals, Inc and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (Filed With SEC on November 6, 2015)
- Form of Warrant (Filed With SEC on November 6, 2015)
- Form of Securities Purchase Agreement, dated as of November 6, 2015, by and between Rexahn Pharmaceuticals, Inc. and the investor in the offering (Filed With SEC on November 6, 2015)
- Third Amendment to Lease Agreement, dated May 6, 2015, by and between Rexahn Pharmaceuticals, Inc. and SG Plaza Holdings, LLC (Filed With SEC on August 7, 2015)
- Employment Agreement dated as of February 2, 2015, by and between Rexahn Pharmaceuticals, Inc. and Ely Benaim, M.D (Filed With SEC on May 8, 2015)
- At Market Issuance Sales Agreement, dated March 16, 2015, by and between Rexahn Pharmaceuticals, Inc. and MLV & CO. LLC (Filed With SEC on March 16, 2015)
- Second Amendment to Lease Agreement, dated July 26, 2014 by and between Rexahn Pharmaceuticals, Inc. and SG Plaza Holdings, LLC (Filed With SEC on November 12, 2014)
- Engagement Letter, dated as of January 14, 2014, by and between Rexahn Pharmaceuticals, Inc. and Roth Capital Partners, LLC (Filed With SEC on January 15, 2014)
- Form of Warrant (Filed With SEC on January 15, 2014)
- Form of Securities Purchase Agreement, dated as of January 15, 2014, by and between Rexahn Pharmaceuticals, Inc. and the investors in the offering (Filed With SEC on January 15, 2014)
- Engagement Letter, dated as of October 10, 2013, by and between Rexahn Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on October 16, 2013)
- Form of Warrant (Filed With SEC on October 16, 2013)
- Lease amendment dated as of June 7, 2013 by and between Rexahn Pharmaceuticals, Inc. and SG Plaza Holdings, LLC (Filed With SEC on August 12, 2013)
- H.C. Wainwright & Co., LLC 570 Lexington Avenue, New York, New York 10022 ###-###-#### www.hcwco.com Member: FINRA, SIPC 1 (Filed With SEC on July 24, 2013)
- COMMON STOCK WARRANT REXAHN PHARMACEUTICALS, INC. (Filed With SEC on July 24, 2013)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 24, 2013)
- Rexahn Pharmaceuticals, Inc. 2013 Stock Option Plan (Filed With SEC on June 11, 2013)
- Employment Agreement by and between Rexahn Pharmaceuticals, Inc. and Dr. Chang H. Ahn, dated as of March 25, 2013 (Filed With SEC on March 29, 2013)
- EMPLOYMENT AGREEMENT (Filed With SEC on January 22, 2013)
- 19,130,435 SHARES OF COMMON STOCK AND 10,521,739 WARRANTS OF REXAHN PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT (Filed With SEC on November 30, 2012)
- COMMON STOCK PURCHASE WARRANT REXAHN PHARMACEUTICALS, INC. (Filed With SEC on November 30, 2012)
- COMMON STOCK PURCHASE WARRANT REXAHN PHARMACEUTICALS, INC. (Filed With SEC on November 30, 2012)
- AMENDMENT NO. 2 TO RESEARCH AND EXCLUSIVE LICENSE OPTION AGREEMENT (Filed With SEC on November 27, 2012)
- Engagement letter, dated as of March 23, 2011, as amended on March 29, 2011, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on March 30, 2011)
- Form of Warrant (Filed With SEC on March 30, 2011)
- Form of Securities Purchase Agreement, dated March 28, 2011, by and between Rexahn Pharmaceuticals, Inc. and the investors in the offering (Filed With SEC on March 30, 2011)
- Amendment No. 2 to the Securities Purchase Agreement, dated January 19, 2011, by and between Rexahn Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited (Filed With SEC on January 20, 2011)
- Amendment No. 1 to the Research and Exclusive License Option Agreement, dated January 19, 2011, by and between Rexahn Pharmaceuticals, Inc. and Teva Pharmaceutical Industries... (Filed With SEC on January 20, 2011)
- Amended and Restated Employment Agreement, dated as of September 9, 2010, by and between Rexahn Pharmaceuticals, Inc. and Chang Ho Ahn (Filed With SEC on September 10, 2010)
- Amended and Restated Employment Agreement, dated as of September 9, 2010, by and between Rexahn Pharmaceuticals, Inc. and Rakesh Soni (Filed With SEC on September 10, 2010)
- Amended and Restated Employment Agreement, dated as of September 9, 2010, by and between Rexahn Pharmaceuticals, Inc. and Tae Heum Jeong (Filed With SEC on September 10, 2010)
- Consulting Agreement, dated February 12, 2010, by and between the Company and JFS Investments (Filed With SEC on August 16, 2010)
- Financial Advisory Services Agreement, dated February 12, 2010, by and Between the Company and Garden State Securities Inc (Filed With SEC on August 16, 2010)
- Engagement letter, dated as of June 27, 2010, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on June 29, 2010)
- Form of Warrant (Filed With SEC on June 29, 2010)
- Form of Securities Purchase Agreement, dated June 28, 2010, by and between Rexahn Pharmaceuticals, Inc. and the investors in the offering (Filed With SEC on June 29, 2010)
- Form of Termination and Release Agreement dated May 17, 2010 (Filed With SEC on May 21, 2010)
- Engagement letter, dated as of October 19, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on October 20, 2009)
- Form of Warrant (Filed With SEC on October 20, 2009)
- Securities Purchase Agreement, dated as of October 19, 2009, by and between Rexahn Pharmaceuticals, Inc. and the purchasers signatory thereto (Filed With SEC on October 20, 2009)
- Research and Exclusive License Option Agreement, dated as of June 26, 2009, by and between Rexahn Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited (Filed With SEC on September 21, 2009)
- Securities Purchase Agreement, dated as of June 26, 2009, by and between Rexahn Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited (Filed With SEC on September 21, 2009)
- Amendment No. 1 to Securities Purchase Agreement, dated as of September 16, 2009, by and between Rexahn Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited (Filed With SEC on September 21, 2009)
- Lease, dated June 5, 2009, by and between Rexahn Pharmaceuticals, Inc. and The Realty Associates Fund V, L.P (Filed With SEC on August 10, 2009)
- Employment Agreement, dated as of August 10, 2009, by and between Rexahn Pharmaceuticals, Inc. and Chang Ho Ahn (Filed With SEC on August 10, 2009)
- Employment Agreement, dated as of August 10, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rakesh Soni (Filed With SEC on August 10, 2009)
- Employment Agreement, dated as of August 10, 2009, by and between Rexahn Pharmaceuticals, Inc. and Tae Heum Jeong (Filed With SEC on August 10, 2009)
- Research and Exclusive License Option Agreement, dated as of June 26, 2009, by and between Rexahn Pharmaceuticals, Inc. and the license optionee named therein (Filed With SEC on June 30, 2009)
- Securities Purchase Agreement, dated as of June 26, 2009, by and between Rexahn Pharmaceuticals, Inc. and the purchaser named therein (Filed With SEC on June 30, 2009)
- Engagement letter, dated as of April 6, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on May 20, 2009)
- Amendment to engagement letter, dated as of May 19, 2009, by and between Rexahn Pharmaceuticals, Inc. and Rodman & Renshaw, LLC (Filed With SEC on May 20, 2009)
- Form of Warrant (Filed With SEC on May 20, 2009)
- Securities Purchase Agreement, dated as of May 19, 2009, by and between Rexahn Pharmaceuticals, Inc. and the purchaser signatory thereto (Filed With SEC on May 20, 2009)
- Consulting Agreement, dated as of August 12, 2008, between Rexahn Pharmaceuticals, Inc. and Y. Michele Kang (Filed With SEC on August 27, 2008)
- Employment Agreement, dated as of July 14, 2008, by and between Rexahn Pharmaceuticals, Inc. and Rakesh Soni (Filed With SEC on July 16, 2008)
- Securities Purchase Agreement, dated as of March 20, 2008, by and between Rexahn Pharmaceuticals, Inc. and Jungwoo Family Co., Ltd. (the Jungwoo Securities Purchase Agreement) (Filed With SEC on March 26, 2008)
- Securities Purchase Agreement, dated as of March 20, 2008, by and between Rexahn Pharmaceuticals, Inc. and Super Bio Co. Ltd., (the Super Bio Securities Purchase Agreement) (Filed With SEC on March 26, 2008)
- Form of Warrant for issuance pursuant to the Jungwoo Securities Purchase Agreement and the Super Bio Securities Purchase Agreement (Filed With SEC on March 26, 2008)
- Warrant, dated December 24, 2007, issued to KT&G Corporation (Filed With SEC on December 26, 2007)
- Warrant, dated December 24, 2007, issued to Rexgene Biotech Co., Ltd (Filed With SEC on December 26, 2007)
- Registration Rights Agreement, dated as of December 24, 2007, by and among Rexahn Pharmaceuticals, Inc. and the purchasers pursuant to the KT&G Securities Purchase Agreement, the... (Filed With SEC on December 26, 2007)
- Securities Purchase Agreement, dated as of December 17, 2007, by and between Rexahn Pharmaceuticals, Inc. and Jungwoo Family Co., Ltd. (the Jungwoo Securities Purchase Agreement) (Filed With SEC on December 18, 2007)
- Securities Purchase Agreement, dated as of December 17, 2007, by and between Rexahn Pharmaceuticals, Inc. and Kumho Investment Bank (the Kumho Securities Purchase Agreement) (Filed With SEC on December 18, 2007)
- Securities Purchase Agreement, dated as of December 17, 2007, by and among Rexahn Pharmaceuticals, Inc. and the several parties signatory thereto (the Individual Investor... (Filed With SEC on December 18, 2007)
- Form of Warrant for issuance pursuant to the Jungwoo Securities Purchase Agreement, the Kumho Securities Agreement and the Individual Investor Securities Purchase Agreement (Filed With SEC on December 18, 2007)
- Form of Registration Rights Agreement for execution pursuant to the Jungwoo Securities Purchase Agreement, the Kumho Securities Agreement and the Individual Investor Securities... (Filed With SEC on December 18, 2007)
- Securities Purchase Agreement, dated as of November 19, 2007, by and between Rexahn Pharmaceuticals, Inc. and KT&G Corporation (Filed With SEC on November 21, 2007)
- Form of Warrant for issuance to KT&G Corporation (Filed With SEC on November 21, 2007)
- Form of Registration Rights Agreement for execution between Rexahn Pharmaceuticals, Inc. and KT&G Corporation (Filed With SEC on November 21, 2007)
- Securities Purchase Agreement, dated as of November 20, 2007, by and between Rexahn Pharmaceuticals, Inc. and Rexgene Biotech Co., Ltd (Filed With SEC on November 21, 2007)
- Form of Warrant for issuance to Rexgene Biotech Co., Ltd (Filed With SEC on November 21, 2007)
- Form of Registration Rights Agreement for execution between Rexahn Pharmaceuticals, Inc. and Rexgene Biotech Co., Ltd (Filed With SEC on November 21, 2007)
- Extension of Stock Option Agreements dated May 2, 2006 by and between Rexahn Pharmaceuticals, Inc. and John Holaday (Filed With SEC on May 5, 2006)
- Employment Agreement, dated September 12, 2005, by and between Rexahn Pharmaceuticals, Inc. and C. H. Ahn (Filed With SEC on September 15, 2005)
- Employment Agreement, dated September 12, 2005, by and between Rexahn Pharmaceuticals, Inc. and T. H. Jeong (Filed With SEC on September 15, 2005)
- Employment Agreement, dated September 12, 2005, by and between Rexahn Pharmaceuticals, Inc. and G. Steinfels (Filed With SEC on September 15, 2005)
- ___________________ CONVERTIBLE NOTE (Filed With SEC on August 11, 2005)
- REXAHN PHARMACEUTICALS, INC. SUBSCRIPTION AGREEMENT (Filed With SEC on August 11, 2005)